(Albany,US) DelveInsight has launched a new report on “Rheumatoid Arthritis (RA) Pipeline Insight, 2020“.
“Rheumatoid Arthritis (RA) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Rheumatoid Arthritis (RA) market. A detailed picture of the Rheumatoid Arthritis (RA) pipeline landscape is provided, which includes the disease overview and Rheumatoid Arthritis (RA) treatment guidelines.
The assessment part of the report embraces in-depth Rheumatoid Arthritis (RA) commercial assessment and clinical assessment of the Rheumatoid Arthritis (RA) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis (RA) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The key players in Rheumatoid Arthritis market are:
Request for Free Sample Report: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight
Drugs covered:
Rheumatoid Arthritis treatment landscape has progressed from the last two decade, including the diagnosis and treatment. Albeit, presently there is no cure for the disease, the goals of therapy are to decrease pain, inflammation control, preserve the ability of the patient to function in activities of daily living and work and avert joint destruction. Pharmacists and other healthcare professionals play a vital role in caring for Rheumatoid Arthritis patients. The pharmacologic approaches have relied on combinations of non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, glucocorticoids (prednisone, methylprednisone), disease-modifying anti-rheumatic drugs (DMARDs) and biologics.
Corticosteroids, including prednisone, prednisolone and methylprednisolone, are potent and quick-acting anti-inflammatory medications. They may be used to get potentially damaging inflammation under control and may be needed to control severe polyarticular disease until disease-modifying antirheumatic drugs (DMARDs) have been added and become useful. There is now a better comprehension of the mechanisms/pathways involved in the disease, permitting site-specific drug development. There are two major types of Disease-Modifying Antirheumatic Drugs (DMARDs): biological and synthetic.
Conventional, synthetic DMARDs (csDMARDs) are not site-specific, and they do not have precise mechanisms of action for relieving the disease. Synthetic DMARDs targets to a particular site. Biological DMARDs are also site-specific (e.g., targeting TNF, IL-6, IL-1, B cells, or T cells).
Key Questions
Table of Contents:
1. Report Introduction
2. Rheumatoid Arthritis (RA)
3. Rheumatoid Arthritis (RA) Current Treatment Patterns
4. Rheumatoid Arthritis (RA) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Rheumatoid Arthritis (RA) Late Stage Products (Phase-III)
7. Rheumatoid Arthritis (RA) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Rheumatoid Arthritis (RA) Discontinued Products
13. Rheumatoid Arthritis (RA) Product Profiles
14. Rheumatoid Arthritis (RA) Key Companies
15. Rheumatoid Arthritis (RA) Key Products
16. Dormant and Discontinued Products
17. Rheumatoid Arthritis (RA) Unmet Needs
18. Rheumatoid Arthritis (RA) Future Perspectives
19. Rheumatoid Arthritis (RA) Analyst Review
20. Appendix
21. Report Methodology
Request for Detailed TOC: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight